With many clinical and regulatory catalysts on the way, the rally we are seeing throughout the biotech sector should gain even more momentum. Last week, every single fund tracking the sector had recorded new highs, and analysts believe that this sentiment could endure for the remainder of the year.
Both the iShares NASDAQ Biotechnology Index (IBB) and the S&P Biotech ETF (XBI) are up around 20%, the Health Care SPDR ETF (XLV) has gained about 17%, while the S&P Pharmaceuticals ETF (XPH) has seen gains of 29% and closed just a penny shy of all-time highs on Friday.
With several biotech companies anticipated to announced news this month, this should add even more steam to the rally we are seeing throughout the sector. Here is a more in depth look at what investors should be watching out for this month.
Biotech Breakroom 